{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04434040","nct_id":"NCT04434040","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04434040. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients will receive the following treatment:\n\nAtezolizumab and Sacituzumab govitecan treatment will continue for 6 cycles (18 total weeks).\n\n* Atezolizumab intravenously (IV) at a pre-determined dose on day 1 in a 21-day cycle\n* Sacituzumab govitecan: intravenously (IV) at a pre-determined dose on days 1 and 8 in a 21-day cycle","label":"Atezolizumab and Sacituzumab govitecan","type":"EXPERIMENTAL"}],"collaborators":["Genentech, Inc.","Stand Up To Cancer"],"completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"conditions":["Breast Cancer","Triple Negative Breast Cancer","Residual Cancer","Circulating Tumor DNA"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Sacituzumab govitecan","otherNames":["Trodelvy, IMMU-132"],"type":"DRUG"}],"last_update":"2026-05-04","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Rate of undetectable circulating tumor cfDNA- 6 Cycles","timeFrame":"18 Weeks"}],"references":[],"start_date":{"date":"2020-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","url":"https://clinicaltrials.gov/study/NCT04434040"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04434040"}